Fortrea Holdings (FTRE) Accumulated Expenses (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Accumulated Expenses came in at $380.8 million in Q2 2026, little changed YoY from $380.8 million in Q2 2025, and up 6.58% on a QoQ basis from $357.3 million in Q1 2026.
Fortrea Holdings (FTRE) Accumulated Expenses (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Accumulated Expenses data on file, last reported at $380.8 million in Q2 2026.
- Quarterly Accumulated Expenses changed 0.0% year-over-year to $380.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $380.8 million (changed 0.0% YoY) and the FY2025 annual result came in at $395.8 million, up 7.03% from the prior year.
- Accumulated Expenses rose to $380.8 million in Q2 2026, from $357.3 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $395.8 million in Q4 2025 to a low of $322.7 million in Q4 2022.
- A 5-year average of $351.9 million and a median of $345.2 million in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Accumulated Expenses slipped 3.78% — and 2025, when it gained 14.39%.
- Tracing FTRE's Accumulated Expenses over 5 years: stood at $322.7 million in 2022, then advanced by 3.97% to $335.5 million in 2023, then increased by 10.22% to $369.8 million in 2024, then climbed by 7.03% to $395.8 million in 2025, then slipped by 3.79% to $380.8 million in 2026.
- The last three Accumulated Expenses figures came in at $380.8 million (Q2 2026), $357.3 million (Q1 2026), and $395.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 380.80 Mn |
| Mar 31, 2026 | 357.30 Mn |
| Dec 31, 2025 | 395.80 Mn |
| Sep 30, 2025 | 369.60 Mn |
| Jun 30, 2025 | 380.80 Mn |
| Mar 31, 2025 | 347.20 Mn |
| Dec 31, 2024 | 369.80 Mn |
| Sep 30, 2024 | 323.10 Mn |
| Jun 30, 2024 | 343.30 Mn |
| Mar 31, 2024 | 328.70 Mn |
| Dec 31, 2023 | 335.50 Mn |
| Sep 30, 2023 | 335.80 Mn |
| Jun 30, 2023 | 336.20 Mn |
| Dec 31, 2022 | 322.70 Mn |